Finance

Lists
Why is MLYS down 4,08%?
Dive Deeper
MLYS:NASDAQ
Mineralys Therapeutics Inc
15,50 $
-4,08%
(-0,66) 1D
15,64 $
+0,90% (+0,14)
Pre-market
Closed: 12 նոյ, 16:00:01 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MLYS...
Open
15,84 $
High
16,88 $
Low
15,18 $
Mkt. cap
1,37 մլրդ
Avg. vol.
1,76 մլն
Volume
220,00
52-wk high
47,00 $
52-wk low
14,91 $
EPS
-4,36 $
Beta
0,83
Shares outstanding
88,56 մլն
No. of employees
76
Open
15,84 $
High
16,88 $
Low
15,18 $
Mkt. cap
1,37 մլրդ
Avg. vol.
1,76 մլն
Volume
220,00
52-wk high
47,00 $
52-wk low
14,91 $
EPS
-4,36 $
Beta
0,83
Shares outstanding
88,56 մլն
No. of employees
76
News stories
From web sources and news partners
About Mineralys Therapeutics Inc
CEO-
Employees76
Founded2019
Headquarters-
SectorHealth Care
Industry-
Websitemineralystx.com
Analyst ratings
Based on 6 analysts giving stock ratings to MLYS in the past 3 months
Strong buy
Buy
5
Hold
1
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for MLYS in the last 3 months.
Highest
Current 15,50 $
56,00 $ (+261,29%)
Average
45,50 $ (+193,55%)
Lowest
19,00 $ (+22,58%)
Analyst
Recommendation
Action
Price target
Projected
Date
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
56,00 $
+261,3%
11/10/2026
Alice Nettleton
UBS
Hold
Reiterated
19,00 $
+22,6%
11/06/2026
Mohit Bansal
Wells Fargo
Buy
Maintained
55,00 $
+254,8%
11/05/2026
Jason Gerberry
Bank of America Securities
Buy
Maintained
-
-
11/05/2026
Tara Bancroft
TD Cowen
Buy
Maintained
-
-
11/05/2026
Annabel Samimy
Stifel Nicolaus
Buy
Reiterated
52,00 $
+235,5%
11/05/2026
Unknown Analyst
UBS
Hold
Initiated
29,00 $
+87,1%
10/11/2026
Seamus Fernandez
Guggenheim
Buy
Reiterated
52,00 $
+235,5%
08/12/2026
Richard Law CFA
Goldman Sachs
Buy
Maintained
40,00 $
+158,1%
08/12/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
55,00 $
+254,8%
08/12/2026
Rami Katkhuda
LifeSci Capital
Buy
Maintained
54,00 $
+248,4%
08/12/2026
Unknown Analyst
Goldman Sachs
Buy
Reiterated
42,00 $
+171%
05/07/2026
Last report
04 նոյ, 2026 թ.
Fiscal period
Q3 2026
-0,64 $ / -0,55 $
-15,91%miss
Revenue / Est. (USD)
- / 0,00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
2026 թ. սեպ
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
24,40 մլն
24,36 մլն
221,38 մլն
22,67 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13,88 մլն
20,98 մլն
24,66 մլն
37,42 մլն
Operating expense
38,28 մլն
45,34 մլն
246,04 մլն
60,09 մլն
Total operating expenses
38,28 մլն
45,34 մլն
246,04 մլն
60,09 մլն
Operating income
-38,28 մլն
-45,34 մլն
-246,04 մլն
-60,09 մլն
Other non operating income
1,00 հզր
5,00 հզր
13,00 հզր
-
EBT including unusual items
-32,23 մլն
-39,34 մլն
-241,07 մլն
-57,33 մլն
EBT excluding unusual items
-32,23 մլն
-39,34 մլն
-241,07 մլն
-57,33 մլն
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-32,23 մլն
-39,34 մլն
-241,07 մլն
-57,33 մլն
Net profit margin
-
-
-
-
Earnings per share
-0,40
-0,47
-2,85
-0,64
Interest and investment income
6,04 մլն
6,00 մլն
4,96 մլն
5,95 մլն
Interest expense
-
-
-
-3,19 մլն
Net interest expenses
6,04 մլն
6,00 մլն
4,96 մլն
2,76 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
-38,27 մլն
-45,33 մլն
-246,04 մլն
-60,08 մլն
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google Apps